Last reviewed · How we verify

Cabazitaxel (XRP6258) — Competitive Intelligence Brief

Cabazitaxel (XRP6258) (Cabazitaxel (XRP6258)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

marketed Taxane; microtubule stabilizer β-tubulin (microtubule) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cabazitaxel (XRP6258) (Cabazitaxel (XRP6258)) — Sanofi. Cabazitaxel is a microtubule-stabilizing taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cabazitaxel (XRP6258) TARGET Cabazitaxel (XRP6258) Sanofi marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Paclitaxel, Carboplatin Paclitaxel, Carboplatin Queensland Centre for Gynaecological Cancer marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin)
Paclitaxel (albumin-bound) Paclitaxel (albumin-bound) Dai, Guanghai marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Docetaxel (DOC) Docetaxel (DOC) Sun Yat-sen University marketed Taxane; microtubule stabilizer β-tubulin
Docetaxel or albumin paclitaxel Docetaxel or albumin paclitaxel Shandong Cancer Hospital and Institute marketed Taxane; microtubule-stabilizing chemotherapy agent β-tubulin (microtubule)
nab-paclitaxel，Cisplatin nab-paclitaxel，Cisplatin Yang Jianjun, PhD marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (cisplatin)
Docetaxel (D) Docetaxel (D) BeyondSpring Pharmaceuticals Inc. marketed Taxane; microtubule stabilizer β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cabazitaxel (XRP6258) — Competitive Intelligence Brief. https://druglandscape.com/ci/cabazitaxel-xrp6258. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: